NCT00004580已完成1 期

Phase I/II Study of ABT-378/Ritonavir in Protease Inhibitor Experienced HIV-Infected Patients

Abbott20 个研究点分布在 1 个国家开始时间: 2001年8月31日最近更新: 2009年2月20日

研究概览

简要总结

The purpose of this study is to see if it is safe and effective to give ABT-378/ritonavir combination plus nevirapine plus two nucleoside transcriptase inhibitors to HIV-infected patients who previously have taken protease inhibitors. This study also examines how the body handles this combination of anti-HIV drugs.

研究设计

研究类型: Interventional
主要目的: Treatment

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

Abbott

申办方类型

Industry

研究点 (20)

Loading locations...

相似试验

已完成

2 期

ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the PastHIV Infections

NCT00004582ViRx

已完成

1 期

ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected SubjectsHIV Infections

NCT00004578Abbott100

已完成

2 期

An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or BuprenorphineChronic Hepatitis C InfectionChronic Hepatitis C

NCT01911845AbbVie38

已完成

3 期

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase InhibitorsHIV Infections

NCT00038636Abbott36

已完成

3 期

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic SuppressionHuman Immunodeficiency Virus (HIV) Infections

NCT00337467Bristol-Myers Squibb61